secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K/A
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001601830-24-000229
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion completes Exscientia acquisition; pro forma shows increased net losses
--------------------------------------------------------------------------------

- Total purchase price ~$635.9M; transaction closed Nov 20, 2024.
- Pro forma 2023 net loss of $548.7M ($1.74/share) vs Recursion standalone $328.1M.
- Pro forma 9M 2024 net loss of $476.5M ($1.32/share) vs Recursion standalone $284.8M.
- Combined total assets ~$1.55B, equity ~$1.14B as of Sept 30, 2024.
- Goodwill of $76.9M and intangible assets of $355.1M recorded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000229/0001601830-24-000229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000229/rxrx-20241119.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer